DNTH vs ERAS Stock Comparison
ERAS currently leads DNTH in this stock comparison, with AIQ scores of 61 vs 56. The clearest difference is quality, while DNTH has the stronger risk resilience profile.
What is the main difference between DNTH and ERAS?
ERAS leads the current stock comparison as Erasca, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Dianthus Therapeutics, Inc. vs Erasca, Inc.
ERAS leads
ERAS leads by 5 AIQ points, primarily on Quality and Momentum, having only recently taken the lead back from DNTH.
Fragile: 1 of 4 evidence groups support ERAS, the lead recently changed hands, and its current signal state is conflicted.
Dianthus Therapeutics, Inc.
Erasca, Inc.
The Algovestiq AIQ Score currently favors ERAS over DNTH, 61 versus 56 as of Nov 15, 2026. ERAS's advantage is driven primarily by stronger quality and momentum, while DNTH holds the stronger risk resilience profile. ERAS also shows the stronger technical structure relative to its 50-day moving average. 1 of 4 covered evidence groups favor ERAS today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 5 points. ERAS lead: Reversed — DNTH led by 8 AIQ points 30 sessions ago; ERAS now leads by 5.
Compare Dianthus Therapeutics, Inc. and Erasca, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare DNTH and ERAS against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience58 vs 39DNTH +19
- Quality52 vs 65ERAS +13
- Momentum58 vs 67ERAS +9
1 of 4 evidence groups favor ERAS. ERAS’s edge is concentrated in quality and momentum; DNTH keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.74x)
- RSI Bearish Divergence — bearish, momentum, medium horizon
Largest factor move: Quality +21
New signals
- ADX Trend Weakening — neutral, trend, medium horizon
- Accumulation Pattern — bullish, volume, medium horizon (1.70x)
The lead changed hands: ERAS moved ahead of DNTH in the latest session.
Deeper signal detail for each name lives on its own signals page — DNTH and ERAS both carry a full feed there.
The central trade-off
ERAS (Erasca, Inc.): the stronger current systematic profile, led by quality and momentum.
DNTH (Dianthus Therapeutics, Inc.): the counter-case, on risk resilience, fundamentals, technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ERASERAS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
DNTHDNTH on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
ERASERAS on the Momentum factor, by 9 points.
Lower downside
DNTHDNTH on Risk Resilience, by 19 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | DNTH | ERAS | Note |
|---|---|---|---|
| Implied upside to target | +46% | — | Level |
| Target dispersion | 0% | — | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 18 | 9 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
1 of 4 covered evidence groups favor ERAS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ERAS | 56 vs 61 |
| Fundamentals | DNTH | EPS growth 10% vs -7.1%; TTM ROE -3.8% vs -5.6% |
| Valuation | Not covered | Not covered |
| Technicals | DNTH | Price vs 50-day 3.8% vs 4.7%; vs 200-day 5.6% vs 2.6% |
| Risk Resilience | DNTH | Risk Resilience 58 vs 39 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of DNTH and ERAS and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
- Only 1 of 4 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ERAS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13ERAS lead: Reversed — DNTH led by 8 AIQ points 30 sessions ago; ERAS now leads by 5.
- Today
- ERAS +5
- 56 vs 61
- 7 sessions ago
- DNTH +2
- 53 vs 51
- 30 sessions ago
- DNTH +8
- 49 vs 41
- 90 sessions ago
- DNTH +11
- 70 vs 59
The lead changed hands 3 times in this window, most recently on Nov 13 when ERAS moved ahead of DNTH.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 2 bearish / 1 neutral, conflicted
Only DNTH
- Golden Cross Active — bullish, trend, long horizon (1.75%)
- Low Volume Rally Warning — bearish, volume, short horizon (0.74x)
- RSI Bearish Divergence — bearish, momentum, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
2 bullish / 2 bearish / 2 neutral, conflicted
Only ERAS
- Death Cross Active — bearish, trend, long horizon (2.00%)
- ADX Trend Weakening — neutral, trend, medium horizon
- Accumulation Pattern — bullish, volume, medium horizon (1.70x)
- Beta Spike Warning — bearish, risk_regime, long horizon
Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish.
ERAS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.72%, AIQ 0 points).
Price is down while the AIQ Score moved up 9 points over the same session — price and model disagree (price -0.76%, AIQ +9 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1DNTH closes the Quality gap — currently 13 points behind, the largest single contributor to ERAS's edge.
- 2DNTH's Low Volume Rally Warning resolves — a bearish volume rule currently active against it.
- 3ERAS's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
DNTH leads on balance| Metric | DNTH | ERAS |
|---|---|---|
| Revenue growth (YoY) | 59% | 0% |
| EPS growth (YoY) | 10% | -7.1% |
| Gross margin | 97.2% | 0% |
| Operating margin | -86.8% | 0% |
| Return on equity (TTM) | -3.8% | -5.6% |
| Debt to equity | 0 | 0.05 |
Performance
ERAS leads 5 of 6 windows| Metric | DNTH | ERAS |
|---|---|---|
| 1 week (5 sessions) | 6.7% | 8.7% |
| 1 month (20 sessions) | 27.4% | 17% |
| 3 months (63 sessions) | -20.1% | -14.3% |
| 6 months (126 sessions) | 6.6% | 53.1% |
| Year to date | 122.8% | 321% |
| 1 year (252 sessions) | 137.1% | 490.9% |
Technicals
DNTH has the stronger structure| Metric | DNTH | ERAS |
|---|---|---|
| RSI (14) | 62.9 | 53.8 |
| ADX (14) | 26.4 | 11.6 |
| Price vs 50-day | 3.8% | 4.7% |
| Price vs 200-day | 5.6% | 2.6% |
| Volatility (1M, annualized) | 39.4% | 81.1% |
Risk
DNTH is the more resilient| Metric | DNTH | ERAS |
|---|---|---|
| Beta | 0.97 | 1.62 |
| Sharpe ratio | 1.82 | 2.29 |
| Sortino ratio | 3.31 | 3.65 |
| Max drawdown | -37.8% | -59.5% |
| Current drawdown | -20.8% | -30.3% |
| Annualized volatility | 59.8% | 102.7% |
| Value at risk (95%) | -4.7% | -6.6% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, DNTH or ERAS?
On the Algovestiq AIQ Score, ERAS is the stronger of the two as of Nov 15, 2026, scoring 61 against DNTH's 56. The edge comes from quality and momentum. DNTH is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is DNTH or ERAS the better buy right now?
ERAS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 1 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 5 points. Treat the lead as provisional.
Why does the AIQ Score favor ERAS over DNTH?
The composite weights Quality, Value, Momentum and Risk Resilience. DNTH leads Risk Resilience by 19 points; ERAS leads Quality by 13 points; ERAS leads Momentum by 9 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, DNTH or ERAS?
Analyst price targets imply +46% upside for DNTH and not covered for ERAS. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, DNTH or ERAS?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, DNTH or ERAS?
DNTH on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, DNTH or ERAS?
ERAS on the Momentum factor, by 9 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, DNTH or ERAS?
DNTH is the more resilient of the two, so the other name carries the higher downside risk. DNTH on Risk Resilience, by 19 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is DNTH more profitable than ERAS?
DNTH leads on the comparable margin measures — gross margin 97.2% vs 0%; operating margin -86.8% vs 0%; ttm roe -3.8% vs -5.6%.
Is ERAS's lead over DNTH getting stronger or weaker?
ERAS lead: Reversed — DNTH led by 8 AIQ points 30 sessions ago; ERAS now leads by 5. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 3 times in that window, most recently on 2026-11-13, when ERAS moved ahead of DNTH.
What would change the DNTH vs ERAS verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: DNTH closes the Quality gap — currently 13 points behind, the largest single contributor to ERAS's edge; DNTH's Low Volume Rally Warning resolves — a bearish volume rule currently active against it; ERAS's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about DNTH and ERAS?
DNTH: 3 bullish / 2 bearish / 1 neutral, conflicted. ERAS: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on DNTH is Golden Cross Active (bullish, long horizon). On ERAS it is Death Cross Active (bearish, long horizon).
Compare DNTH and ERAS with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.